tbuckley/cabot-search huggingface dataset:
P-172 A multi-center, open-label, randomized controlled trial of nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine for first-line treatment of advanced pancreatic cancer (PC)
Authors: M. Jin, H. Liu, Z. Lin, J. Xue, J. Liu, L. Bao, Z. Luo, X. Yu, S. Li, J. Hu, T. Zhang
Journal: Annals of Oncology (2022)
Reclassifying inconclusive diagnosis for cystic fibrosis with new generation sweat test
Authors: Thao Nguyen-Khoa, Aurélie Hatton, David Drummond, Laura Aoust, Joël Schlatter, Clémence Martin, Sophie Ramel, Sébastien Kiefer, Elsa Gachelin, Nathalie Stremler, Laure Cosson, Asma Gabsi, Natascha Remus, Myriam Benhamida, Alice Hadchouel, Isabelle Fajac, Anne Munck, Emmanuelle Girodon, Isabelle Sermet-Gaudelus
Journal: European Respiratory Journal (2022)

<b>The evaporimetric beta-adrenergic sweat secretion test is feasible, safe, and accurate. It provides a valuable complementary test for proper classification of patients with CF-like symptoms presenting borderline SCC but inconclusive genetic test results.</b>https://bit.ly/3vMyXx5
The association between immunosuppressants and outcomes of COVID-19
Authors: Chi-Kuei Hsu, Chih-Cheng Lai
Journal: European Respiratory Journal (2022)

We read with great interest the study investigating the association between immunosuppressant and the outcome of patients withs SARS-CoV-2 infection [1]. They found that the prior use of immunosuppressant would be associated with a significantly increased risk of death (adjusted relative risk [RR], 1.56; 95% CI, 1.10–2.22) which was mainly driven by exposure to systemic glucocorticoids (aRR, 2.38; 95% CI 1.72–3.30). Overall, it is a well-designed study; however, we have three concerns about the findings of this study.
O-6 Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of unresectable RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients: Results of the phase III randomized TRIPLETE study by GONO
Authors: D. Rossini, C. Antoniotti, S. Lonardi, F. Pietrantonio, F. Marmorino, L. Antonuzzo, A. Boccaccino, G. Randon, E. Giommoni, C. Pozzo, R. Moretto, M. De Grandis, M. Viola, A. Passardi, B. Borelli, A. Buonadonna, G. Masi, V. Formica, G. Aprile, L. Boni, C. Cremolini
Journal: Annals of Oncology (2022)
P-7 Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal cancer: Update on the first real-world study in Germany and Austria – BERING CRC
Authors: E. von der Heyde, D. Bürkle, H. Forstbauer, G. Hübner, B. Schmidt, J. Schröder, A. Distelrath, J. Wierecky, P. Stübs, J. Kisro, M. Welslau, H. Müller-Huesmann, T. Göhler, B. Krammer-Steiner, I. Schwaner, C. Hering-Schubert, A. Gerger, R. Greil, L. Jacobasch, F. Reichenbach, S. Stintzing, G. Prager
Journal: Annals of Oncology (2022)

For the therapy of previously treated BRAF V600E-mutant metastatic colorectal cancer, the combination of encorafenib with cetuximab represents a new standard of care. The combination of encorafenib plus cetuximab was approved in the EU in June 2020. The approval was based on positive results from the BEACON CRC trial, which demonstrated a median overall survival (OS) of 8.4 mo (second data cut off 9.3 mo) and an objective response rate of 20% (both data cut offs). The observed tolerability profile was consistent with the known safety profile of each agent. Since data from controlled clinical trials are based on a selected patient population, the present non-interventional study (NIS) investigates the use of encorafenib + cetuximab under real-world conditions in a broader patient population. BERING CRC is an ongoing, multi-national, multi-centric, prospective, longitudinal NIS. It represents the first NIS to investigate the real-world use of the targeted therapy encorafenib + cetuximab in BRAF V600E-mutant metastatic colorectal cancer after prior systemic treatment in Germany and Austria. The project aims to enroll up to 500 patients from 90 German and Austrian sites with a total study duration of approx. 6 yrs. From Sep 2020 to Feb 2022, 72 patients have been included from 80 open sites. The study follows patients treated according to the SmPCs (Summary of Product Characteristics) and the primary objective is to assess the 1-year OS rate. Additional analyses include efficacy, quality of life, safety and tolerability of encorafenib + cetuximab treatment. The influence of prognostic factors on efficacy, safety and tolerability will also be analyzed. NCT04673955. Pierre Fabre Pharma. This study is funded by Pierre Fabre Pharma GmbH (Freiburg, Germany) and Pierre Fabre Pharma Austria (Wels, Austria).
SO-5 Disease-free survival as surrogate for overall survival in neoadjuvant chemo(radio)therapy treatment of esophageal or gastro-esophageal junction carcinoma: An analysis of 4518 individual patients and 22 trials
Authors: N. Cabrit, M. Faron, J. Tierney, M. Cheugoua-Zanetsie, P. Thirion, D. Cunningham, K. Winter, J. Fu, M. Mauer, J. Shapiro, B. Burmeister, T. Walsh, G. Piessen, F. Klevebro, M. Ychou, A. Van Der Gaast, S. Law, M. Stahl, X. Paoletti, M. Ducreux, S. Michiels
Journal: Annals of Oncology (2022)
SO-9 Pathological primary tumour and lymph node regression following neoadjuvant chemotherapy in resectable oesophagogastric cancer: Pooled analysis of 1619 patients from two randomised trials
Authors: A. Athauda, M. Nankivell, S. Pritchard, R. Langer, R. Langley, K. Von Loga, N. Starling, I. Chau, D. Cunningham, H. Grabsch
Journal: Annals of Oncology (2022)

No definitive largescale data exists evaluating the role of pathologically defined regression changes within lymph nodes (LN) of resected oesophagogastric (OG) adenocarcinoma following neoadjuvant chemotherapy. There is also a lack of centralised data assessing the relationship between tumour and LN regression changes and their impact on survival in localised OG cancer. Data and samples from two large prospective randomised trials in resectable OG adenocarcinoma (UK MRC OE05 and ST03 trials) were pooled using a two-stage meta-analysis. H&E stained slides were available for central review from 1619 patients who underwent surgical resection following neoadjuvant chemotherapy. Mandard tumour regression grade (TRG) and LN regression ((LNR) scored as present/absent) were assessed centrally and correlated with survival using a Cox model to obtain hazard ratios. An exploratory analysis to assess whether the available results could define subgroups with distinct prognoses was conducted using a classification and regression tree (CART) analysis. 19,489 H&E slides from 761 OE05 participants and 20,277 slides from 858 ST03 participants were reviewed centrally. Within ST03, there was no difference between treatment arm (ECX ± Bev) in terms of TRG score or LNR. Within OE05, ECX was associated with lower TRG score and higher rates of LNR than CF. Neither trial demonstrated a correlation between TRG score and the presence or absence of LNR. In univariable analysis, lower TRG score, lower pathological N-stage (pN), lower pathological T-stage (pT), the presence of LNR, a well/moderately differentiated tumour, and achieving an R0 resection were all associated with significantly increased survival. However, multivariable analysis found that only pN, pT, differentiation and R0 were independent indicators of prognosis. Importantly, pN stage at resection significantly improved survival (3-year OS for ypN0 74% vs 36% for ypN1+, HR 3.4, p Exploratory CART analysis identified six subgroups based on the prognostic variables above, with 3-year OS ranging from 83% to 22%; with the most important single prognostic variable being pathological N-stage. This study represents the largest central review of primary tumour and LN regression in early OG cancer from patients treated with neoadjuvant chemotherapy within randomised controlled trials. pN and pT stage, tumour differentiation, and resection status in the post-operative specimen are strong independent indicators of survival in multivariate analysis. Exploratory CART analysis can be used to define groups with differing prognoses. Our results suggest that the assessment of LNR and TRG is not necessary to define prognosis further.
Excessive IL-10 and IL-18 trigger hemophagocytic lymphohistiocytosis–like hyperinflammation and enhanced myelopoiesis
Authors: Yuting Tang, Qian Xu, Hui Luo, Xiaomei Yan, Gaoxiang Wang, Liang Hu, Jin Jin, David P. Witte, Rebecca A. Marsh, Liang Huang, Gang Huang, Jianfeng Zhou
Journal: Journal of Allergy and Clinical Immunology (2022)
P-45 Microsatellite instability and HER2 status in radically resectable locally advanced esophago-gastric adenocarcinoma: A single-center experience
Authors: L. Gervaso, L. Bottiglieri, M. Meneses, S. Pellicori, R. Biffi, U. Fumagalli Romario, I. Sala, V. Bagnardi, C. Cella, N. Fazio
Journal: Annals of Oncology (2022)
P-145 Modified FOLFIRINOX as neoadjuvant treatment in patients with borderline resectable and locally advanced pancreatic adenocarcinoma: A single-center study
Authors: S. Ioannou, G. Papaxoinis, D. Korkolis, D. Kypreos, P. Gouveris, D. Zouki, V. Kardara, K. Exarchos, G. Karianakis, I. Bitsas, V. Adamou, G. Koronakis, N. Stavrou, S. Demiri
Journal: Annals of Oncology (2022)
High-Sensitivity Cardiac Troponin and the 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guidelines for the Evaluation and Diagnosis of Acute Chest Pain
Authors: Yader Sandoval, Fred S. Apple, Simon A. Mahler, Richard Body, Paul O. Collinson, Allan S. Jaffe
Journal: Circulation (2022)

The 2021 American Heart Association/American College of Cardiology/American Society of Echocardiography/American College of Chest Physicians/Society for Academic Emergency Medicine/Society of Cardiovascular Computed Tomography/Society for Cardiovascular Magnetic Resonance guidelines for the evaluation and diagnosis of acute chest pain make important recommendations that include the recognition of high-sensitivity cardiac troponin (hs-cTn) as the preferred biomarker, endorsement of 99th percentile upper reference limits to define myocardial injury, and the use of clinical decision pathways, as well as acknowledgment of the uniqueness of women and other patient subsets. Details on how to integrate hs-cTn into clinical practice are less extensively addressed. Clinicians should be aware of some of the analytical aspects related to hs-cTn assays regarding the limit of detection and the limit of quantitation and how they are used clinically, especially for the single sample strategy to rule out acute myocardial infarction. Likewise, it is important for clinicians to understand issues related to the derivation of the 99th percentile upper reference limit; the value of sex-specific 99th percentile upper reference limits; how to use changing concentrations (deltas) to facilitate diagnosis and risk stratification of patients with suspected acute coronary syndrome, including the differentiation of acute from chronic myocardial injury; and how to best integrate the use of hs-cTn with clinical decision pathways. With the use of hs-cTn, conditions such as type 2 myocardial infarction become more common, whereas others such as unstable angina become less frequent but still occur. Sections relating to these issues are included.
P-34 Does the chemotherapeutic efficacy of trifluridine/tipiracil plus bevacizumab change depend on pre-treatment vascular endothelial growth factor inhibitors?
Authors: H. Osumi, O. Akira, K. Shimozaki, I. Nakayama, T. Wakatsuki, D. Takahari, K. Chin, K. Yamaguchi, E. Shinozaki
Journal: Annals of Oncology (2022)
P-133 Clinical responses in pancreaticobiliary cancer patients who received bintrafusp alfa (BA) or BA plus CXCR1/2 inhibitor (SX-682) plus CEA/MUC1-targted vaccine (CV301)
Authors: J. Redman, A. Spira, M. Javle, K. Kelly, N. Pavlakis, G. Jehl, M. Gatti-Mays, L. Cordes, C. Alewine, C. Pico-Navarro, J. Zebala, R. Ito, J. Marte, J. Strauss, C. Floudas, D. Pastor, D. Francis, E. Redmond, J. Gulley, J. Schlom
Journal: Annals of Oncology (2022)
A traction device to aid the intubation of a surgically altered bile duct during ERCP
Authors: Tsuyoshi Suda, Masahiro Yanagi, Naoki Oishi, Eiki Matsushita
Journal: Endoscopy (2022)

A 92-year-old woman was admitted for acute cholangitis with multiple common bile duct (CBD) stones. We performed endoscopic retrograde cholangiopancreatography (ERCP) using a front-viewing endoscope (PCF-Q260AZI; Olympus, Tokyo, Japan) because she had undergone distal gastrectomy with Billroth II reconstruction. However, the ampulla of Vater was not fixed in front, making it difficult to intubate the CBD ([Fig. 1]). Computed tomography and magnetic resonance cholangiopancreatography showed kinking of the lower end of the CBD due to surgical manipulation ([Fig. 2]). Thus, traction was applied via a traction device (S-O clip; Zeon Medical Inc., Tokyo, Japan), which was connected to the oral side of the ampulla of Vater; the loop of the clip was grasped ([Fig. 3 a]) and secured proximally for traction ([Fig. 3 b]). As a result, the torsion of the CBD resolved, and the ampulla of Vater could be viewed from the front ([Fig. 4 a]). The CBD was then easily intubated ([Fig. 4 b]) and a plastic stent was placed for drainage.
SO-12 Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients with advanced hepatocellular carcinoma (aHCC): 5-year results from CheckMate 040
Authors: I. Melero, T. Yau, Y. Kang, T. Kim, A. Santoro, B. Sangro, M. Kudo, M. Hou, A. Matilla, F. Tovoli, J. Knox, A. He, B. El-Rayes, M. Acosta-Rivera, H. Lim, S. Soleymani, J. Yao, J. Neely, M. Tschaika, C. Hsu, A. El-Khoueiry
Journal: Annals of Oncology (2022)
Double-balloon enteroscopy-assisted polypectomy for a solitary jejunal Peutz–Jeghers polyp causing anemia
Authors: Kazunori Onuma, Gota Sudo, Hiroyuki Inoue, Takahiro Kuriyama, Yumemi Takada, Atsushi Yawata, Hiroshi Nakase
Journal: Endoscopy (2022)

A 53-year-old man with no family history of hereditary disease was referred to our hospital for evaluation of anemia. He had a 2-year history of postprandial nausea and discomfort in the upper abdomen. There was no hyperpigmentation of the oral mucosa or skin on physical examination. Esophagogastroduodenoscopy and colonoscopy performed at his previous hospital had revealed no specific findings. Laboratory data showed iron deficiency anemia, with a hemoglobin level of 6.0 g/dL. Abdominal computed tomography was unremarkable.
Combination of ERCP with endoscopic ultrasound-guided hepaticogastrostomy and hepaticoduodenostomy for biliary drainage in malignant hilar biliary obstruction
Authors: Haruka Toyonaga, Tsuyoshi Hayashi, Toshifumi Kin, Kazuki Hama, Kosuke Iwano, Risa Nakamura, Akio Katanuma
Journal: Endoscopy (2022)

Among patients with malignant hilar biliary obstruction, those suffering from cholangitis sometimes require decompression of all divided biliary branches; however, the achievement of this by endoscopic retrograde cholangiopancreatography (ERCP) alone is difficult in patients with severe biliary obstruction, such as Bismuth types III and IV [1]. In such cases, combining ERCP and percutaneous transhepatic biliary drainage (PTBD) is common; however, PTBD has been associated with a decreased quality of life. Endoscopic ultrasound (EUS)-guided procedures are widely performed [2], and there are increasing reports that EUS-guided biliary drainage (EUS-BD) is useful in patients with malignant hilar biliary obstruction [3] [4] [5].
Endoscopic submucosal dissection for complete removal of a residual colorectal tumor involving a diverticulum
Authors: Kazuya Hosotani, Yohei Yabuuchi, Daisuke Yamashita, Shigeo Hara, Tetsuro Inokuma
Journal: Endoscopy (2022)

A 74-year-old man underwent endoscopic mucosal resection (EMR) for treatment of a 20-mm polyp close to a diverticulum in the ascending colon. Surveillance colonoscopy at 12 months showed a 10-mm polyp involving a diverticulum and surrounded by scars in the ascending colon ([Fig. 1 a]). Because the lesion was completely involving a diverticulum and water immersion could not show the "floating" effect on the tumor associated with the diverticulum [1], underwater EMR (UEMR) was discontinued. In addition, submucosal injection showed the nonlifting sign [2].
Associations of hiatus hernia with CT-based interstitial lung changes: the MESA Lung Study
Authors: John S. Kim, Jinhye Kim, Xiaorui Yin, Grant T. Hiura, Michaela R. Anderson, Eric A. Hoffman, Ganesh Raghu, Imre Noth, Ani Manichaikul, Stephen S. Rich, Benjamin M. Smith, Anna J. Podolanczuk, Christine Kim Garcia, R. Graham Barr, Martin R. Prince, Elizabeth C. Oelsner
Journal: European Respiratory Journal (2022)

Background Hiatus hernia (HH) is prevalent in adults with pulmonary fibrosis. We hypothesised that HH would be associated with markers of lung inflammation and fibrosis among community-dwelling adults and stronger among MUC5B (rs35705950) risk allele carriers. Methods In the Multi-Ethnic Study of Atherosclerosis, HH was assessed from cardiac and full-lung computed tomography (CT) scans performed at Exam 1 (2000–2002, n=3342) and Exam 5 (2010–2012, n=3091), respectively. Percentage of high attenuation areas (HAAs; percentage of voxels with attenuation between −600 and −250 HU) was measured from cardiac and lung scans. Interstitial lung abnormalities (ILAs) were examined from Exam 5 scans (n=2380). Regression models were used to examine the associations of HH with HAAs, ILAs and serum matrix metalloproteinase-7 (MMP-7), and adjusted for age, sex, race/ethnicity, educational attainment, smoking, height, weight and scanner parameters for HAA analysis. Results HH detected from Exam 5 scans was associated with a mean percentage difference in HAAs of 2.23% (95% CI 0.57–3.93%) and an increase of 0.48% (95% CI 0.07–0.89%) per year, particularly in MUC5B risk allele carriers (p-value for interaction=0.02). HH was associated with ILAs among those &lt;80 years of age (OR for ILAs 1.78, 95% CI 1.14–2.80) and higher serum MMP-7 level among smokers (p-value for smoking interaction=0.04). Conclusions HH was associated with more HAAs over time, particularly among MUC5B risk allele carriers, and ILAs in younger adults, and may be a risk factor in the early stages of interstitial lung disease.
SO-13 Pembrolizumab in patients with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the open-label, phase 2 KEYNOTE-224 study
Authors: A. Vogel, J. Edeline, S. Ogasawara, M. Kudo, R. Finn, D. Palmer, C. Verslype, V. Zagonel, L. Fartoux, D. Sarker, G. Verset, S. Chan, J. Knox, A. Cheng, B. Daniele, T. Yau, A. Wang, K. Hatogai, A. Siegel, S. Cattan
Journal: Annals of Oncology (2022)
P-264 The molecular-metabolic interplay in metastatic gastrointestinal stromal tumors (GISTs): The predictive role of body mass index
Authors: L. Incorvaia, C. Brando, L. Algeri, A. Dimino, E. Pedone, R. Schiacchitano, L. Magrin, A. Fiorino, A. Perez, N. Barraco, M. Bono, D. Cancelliere, A. Pivetti, T. Bazan Russo, S. Contino, V. Gristina, A. Galvano, V. Bazan, A. Russo, G. Badalamenti
Journal: Annals of Oncology (2022)
P-204 Outcomes of geriatric population with resectable colorectal liver metastases cancer: Data from real life
Authors: M. Costa, A. Valente, I. Costa, M. Freitas, C. Almeida, M. Goncalves, C. Fernandes, J. Reis, C. Teixeira, N. Tavares, C. Sarmento, M. Barbosa
Journal: Annals of Oncology (2022)
SO-19 Biomarker analysis using plasma angiogenesis factors in the TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab as second-line treatment for metastatic colorectal cancer
Authors: H. Taniguchi, Y. Kuboki, J. Watanabe, T. Terazawa, H. Kawakami, M. Yokota, M. Nakamura, M. Kotaka, N. Sugimoto, H. Ojima, E. Oki, T. Kajiwara, T. Moriwaki, T. Takayama, T. Denda, T. Tamura, Y. Sunakawa, S. Ishihara, T. Nakajima, S. Morita, K. Shirao, T. Yoshino
Journal: Annals of Oncology (2022)

In primary analysis from the TRUSTY study, trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) failed to show non-inferiority in terms of overall survival (OS) to irinotecan and fluoropyrimidine plus BEV as second-line treatment in patients (pts) with metastatic colorectal cancer (mCRC) who failed first-line chemotherapy with fluoropyrimidine and oxaliplatin plus either BEV or an anti-EGFR antibody (median OS: 14.8 vs. 18.1 months; hazard ratio [HR]: 1.38; 95% CI: 0.99–1.93; p = 0.59 for non-inferiority; Kuboki Y et al., ASCO 2021). Here we report the relationship between the plasma levels of angiogenesis-related factors and the efficacy of FTD/TPI plus BEV in mCRC. Pts who provided informed consent for the biomarker research were included in this analysis. Plasma samples were collected prior to the start of study treatment. Comprehensive measurements of 17 factors (Angiopoietin-2, HGF, IFN-γ, IL-6, IL-8, PlGF, VEGF-A, VEGF-D, OPN, sNeuropilin-1, sVEGFR1, sVEGFR2, sVEGFR3, TSP-2, sICAM-1, sVCAM-1, TIMP-1) were performed using a multiplex assay with Luminex® technology. The cut-off value in this analysis was defined as the median value of each factor. Disease control rate (DCR) and progression-free survival (PFS) as measures of the efficacy of FTD/TPI plus BEV were compared between 2 groups with high and low levels of each marker. In the FTD/TPI plus BEV arm, plasma samples were available for 65 of the intention-to-treat population (N=197). Baseline characteristics were male/female: 35/30, median age: 64.0 (range: 25–84), RAS status wild-type/mutant: 29/36, and anti-EGFR antibody/bevacizumab in first-line treatment: 17/48. The DCR was 55.4% and median PFS was 3.9 months in the population for this biomarker analysis. A higher DCR was observed in pts with lower HGF (72.0 vs. 39.4%, risk ratio: 1.83; 95% CI: 1.12–2.98) and lower IL-8 (67.9 vs. 40.0%, risk ratio: 1.70; 95% CI: 1.02–2.82). The PFS was significantly longer in pts with lower HGF (5.5 vs. 3.3 months, HR: 0.33; 95% CI: 0.14–0.79) and lower IL-8 (5.5 vs. 3.3 months, HR: 0.31; 95% CI: 0.14–0.70). In addition, pts with low levels of IL-6 (6.0 vs. 3.5 months, HR: 0.19; 95% CI: 0.07–0.50), OPN (5.5 vs. 3.5 months, HR: 0.39; 95% CI: 0.17–0.88), TSP-2 (4.9 vs. 3.6 months, HR: 0.42; 95% CI: 0.18–0.98), and TIMP-1 (7.4 vs. 3.6 months, HR: 0.26; 95% CI: 0.10–0.67) had longer PFS. Plasma levels of HGF and IL-8 at baseline may serve as a predictor for better DCR and PFS of FTD/TPI plus BEV as second-line treatment in pts with mCRC, although further studies are warranted.
P-121 Effects of tumor treating fields (TTFields) on gastric cancer cells and their potential concomitant application with FOLFOX
Authors: N. Flint-Brodsly, E. Zeevi, E. Dor-On, R. Schneiderman, M. Munster, Y. Porat, T. Voloshin, S. Davidi, J. León, A. Haber, M. Giladi, U. Weinberg, Y. Palti
Journal: Annals of Oncology (2022)
Improving Treatment Options for Primary Hyperoxaluria
Authors: Bernd Hoppe, Cristina Martin-Higueras
Journal: Drugs (2022)

The primary hyperoxalurias are three rare inborn errors of the glyoxylate metabolism in the liver, which lead to massively increased endogenous oxalate production, thus elevating urinary oxalate excretion and, based on that, recurrent urolithiasis and/or progressive nephrocalcinosis. Frequently, especially in type 1 primary hyperoxaluria, early end-stage renal failure occurs. Treatment possibilities are scare, namely, hyperhydration and alkaline citrate medication. In type 1 primary hyperoxaluria, vitamin B
P-26 HERIZON-GEA-01: A phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (GEA)
Authors: J. Tabernero, E. Elimova, G. Ku, K. Shitara, L. Shen, T. Liu, X. Lin, L. Boyken, H. Li, J. Grim, J. Ajani
Journal: Annals of Oncology (2022)
P-5 Phase II study (daNIS-1) of the anti-TGF-β monoclonal antibody (mAb) NIS793 +/- spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)
Authors: S. Sivakumar, T. Macarulla, P. Grell, C. Chee, A. Krishnamurthy, M. Ka Wong, M. Michael, M. Milella, G. Prager, C. Springfeld, J. Collignon, J. Siveke, A. Santoro, C. Lin, K. Peltola, G. Bostel, D. Jankovic, M. Altzerinakou, C. Fabre, L. Bai
Journal: Annals of Oncology (2022)